위마비 치료제 시장 규모, 점유율, 성장 분석, 유형별, 약제 클래스별, 투여 경로별, 용도별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Gastroparesis Drugs Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Drug Class (Amino salicylates, Digestive enzymes), By Route of Administration, By Application, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1755468
리서치사:SkyQuest
발행일:2025년 06월
페이지 정보:영문 192 Pages
라이선스 & 가격 (부가세 별도)
한글목차
위마비 치료제 세계 시장 규모는 2023년에 57억 달러, 2024년 60억 1,000만 달러에서 2032년에는 92억 3,000만 달러로 성장하고, 예측 기간(2025-2032년) CAGR은 5.5%를 나타낼 전망입니다.
위마비 치료제 시장은 위마비의 주요 원인인 당뇨병의 유병률 증가와 위장 질환에 대한 인식이 높아짐에 따라 안정적인 성장이 예상됩니다. 메스꺼움, 복부 팽만감, 위 배출 지연을 관리하기 위한 효과적인 솔루션으로 양성자 펌프 억제제 및 프로키네틱 제제가 부상하고 있으며, 비침습적이고 증상에 초점을 맞춘 치료법에 대한 수요는 지속적으로 증가하고 있습니다. 당뇨병 관련 합병증이 증가하고 있는 가운데, 당뇨병성 위부전 마비가 적응증 중 가장 많은 비중을 차지하고 있다는 점은 주목할 만합니다. 소매 약국이 여전히 주요 유통 채널이지만, 온라인 약국이 편리성으로 인해 선호도가 높아지고 있습니다. 경쟁 구도에서는 주요 제약사들이 연구개발과 전략적 제휴에 투자하여 진화하는 환자 니즈에 대응하고 있습니다. 북미는 강력한 의료 시스템과 첨단 치료법을 바탕으로 시장을 선도하고 있으며, 유럽(특히 독일과 영국)도 환자 치료에 있어 상당한 진전을 보이고 있습니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
위마비 치료제 시장 규모 : 유형별&CAGR(2025-2032년)
시장 개요
브랜드
제네릭
위마비 치료제 시장 규모 : 약제 클래스별&CAGR(2025-2032년)
시장 개요
아미노 살리실산염
소화 효소
양성자 펌프 억제제
설사약
제토제
H2 길항제
지사제
생물제제 및 바이오시밀러
기타
위마비 치료제 시장 규모 : 투여 경로별&CAGR(2025-2032년)
시장 개요
경구
주사
기타
위마비 치료제 시장 규모 : 용도별&CAGR(2025-2032년)
시장 개요
크론병
궤양성 대장염
역류성 식도염
IBS
기타
위마비 치료제 시장 규모 : 유통 채널별&CAGR(2025-2032년)
시장 개요
병원 약국
소매 약국
온라인 약국
위마비 치료제 시장 규모&CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
AbbVie Inc.(미국)
Evoke Pharma, Inc.(미국)
Vanda Pharmaceuticals Inc.(미국)
Takeda Pharmaceutical Company Limited(일본)
AstraZeneca PLC(영국)
GlaxoSmithKline PLC(GSK)(영국)
Neurogastrx Inc.(미국)
Processa Pharmaceuticals, Inc.(미국)
Abbott Laboratories(미국)
Bausch Health Companies Inc.(캐나다)
Rhythm Pharmaceuticals, Inc.(미국)
CinDome Pharma(미국)
ANI Pharmaceuticals, Inc.(미국)
Johnson & Johnson Inc.(미국)
Pfizer Inc.(미국)
Teva Pharmaceutical Industries Ltd.(이스라엘)
Medtronic PLC(아일랜드)
Otsuka Pharmaceutical Co. Ltd.(일본)
Theravance Biopharma, Inc.(미국)
Cadila Pharmaceuticals(인도)
결론과 제안
LSH
영문 목차
영문목차
Global Gastroparesis Drugs Market size was valued at USD 5.7 billion in 2023 and is poised to grow from USD 6.01 billion in 2024 to USD 9.23 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).
The gastroparesis drugs market is poised for steady growth, largely propelled by the rising prevalence of diabetes, a leading factor behind gastroparesis, coupled with heightened awareness of gastrointestinal disorders. The demand for non-invasive, symptom-focused therapies continues to rise, with proton pump inhibitors and prokinetic agents emerging as effective solutions for managing nausea, bloating, and delayed gastric emptying. Notably, diabetic gastroparesis dominates the indication segment amid increasing diabetes-related complications. Retail pharmacies remain the primary distribution channel, yet online pharmacies are gaining traction for their convenience. The competitive landscape features major pharmaceutical companies investing in R&D and strategic partnerships to address evolving patient needs. North America leads the market, supported by strong healthcare systems and advanced treatments, while Europe, particularly Germany and the UK, also showcases significant advancements in patient care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroparesis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gastroparesis Drugs Market Segments Analysis
Global Gastroparesis Drugs Market is segmented by Type, Drug Class, Route of Administration, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generics. Based on Drug Class, the market is segmented into Amino salicylates, Digestive enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics/Biosimilar and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Application, the market is segmented into Crohn's disease, Ulcerative colitis, GERD, IBS and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gastroparesis Drugs Market
A significant factor propelling the Global Gastroparesis Drugs market is the increasing prevalence of diabetes, which has a strong association with the condition of gastroparesis. As the number of individuals diagnosed with Type 1 and Type 2 diabetes rises worldwide, the occurrence of related complications, such as diabetic gastroparesis, is becoming more pronounced, thus creating a heightened demand for effective medical treatments. A report from the International Diabetes Federation in January 2024 highlighted a surge in diabetes cases globally, particularly in regions like Asia and North America. This trend has prompted pharmaceutical companies, including Evoke Pharma, to enhance the production of medications like Gimoti, focusing specifically on addressing diabetic gastroparesis.
Restraints in the Global Gastroparesis Drugs Market
The Global Gastroparesis Drugs market faces significant challenges due to the limitations of currently available treatments, which primarily provide symptomatic relief while often causing undesirable side effects that discourage long-term use and diminish overall patient satisfaction. Additionally, regulatory obstacles persist, as evidenced by the FDA's April 2024 decision to reject the approval of a new prokinetic agent from PharmaNova, citing insufficient long-term safety data. This situation highlights the complexities involved in developing new and effective therapies, underscoring the difficulties that pharmaceutical companies encounter in navigating the regulatory landscape to bring safe and innovative treatments to market.
Market Trends of the Global Gastroparesis Drugs Market
The Global Gastroparesis Drugs market is undergoing a significant transformation, driven by the integration of artificial intelligence in drug discovery and clinical trial design. As pharmaceuticals grapple with the complexities of tailoring treatments for this multifaceted disorder, AI technologies are revolutionizing R&D processes. Recent collaborations, such as Quris-AI's partnership with NeuroGasTx, exemplify this trend, demonstrating how AI can enhance patient simulations and optimize trial efficiency. Such innovations have led to a 25% increase in enrollment rates and reduced costs, thereby accelerating the development timeline for new therapies. This shift towards AI-driven methodologies is expected to enhance treatment efficacy and patient outcomes in the gastroparesis market.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Gastroparesis Drugs Market Size by Type & CAGR (2025-2032)
Market Overview
Branded
Generics
Global Gastroparesis Drugs Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Amino salicylates
Digestive enzymes
Proton Pump Inhibitors
Laxatives
Anti-Emetics
H2 Antagonists
Anti-Diarrheal
Biologics/Biosimilar
Others
Global Gastroparesis Drugs Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Others
Global Gastroparesis Drugs Market Size by Application & CAGR (2025-2032)
Market Overview
Crohn's disease
Ulcerative colitis
GERD
IBS
Others
Global Gastroparesis Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Gastroparesis Drugs Market Size & CAGR (2025-2032)
North America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
US
Canada
Europe (Type, Drug Class, Route of Administration, Application, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Drug Class, Route of Administration, Application, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Type, Drug Class, Route of Administration, Application, Distribution Channel)
